AGENDA | Kisaco Research

AGENDA

DOWNLOAD THE 2025 PROGRAM 

 

Your journey to wound care innovation starts here

AGENDA SNEAK PEEK

Filter by:

Here's a sneak peek of our 2024 agenda... Download our full agenda below to find out more!

  • Tuesday, 16 Apr, 2024
    9:00am

    Shaping the Future of Advanced Wound Care

    • Investigate cutting-edge wound care tech and personalized medicine.
    • Navigate changing regulations, prioritize standardized protocols, and promote patient engagement through education and home-based care.
    • Evaluate economic impacts, enhance reimbursement models, and address accessibility challenges

    Author:

    Kevin Richardson

    CEO
    Qualigen Therapeutics
    ... read more

    Kevin Richardson

    CEO
    Qualigen Therapeutics

    Author:

    Emma Wright

    CMO
    Mölnlycke

    Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

    ... read more

    Emma Wright

    CMO
    Mölnlycke

    Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

    Author:

    Kris Kieswetter

    Senior Director, Research and Technology
    3M
    ... read more

    Kris Kieswetter

    Senior Director, Research and Technology
    3M
    9:40am

    Shaping the Future of Advanced Wound Care

    • Emphasize the importance of regulatory bodies adapting to facilitate swift approvals for evolving wound care innovations, aligning standards with technology advancements.
    • Explore the mutually beneficial link between regulatory backing and industry growth

    Author:

    Julie Morabito

    Assistant Director
    FDA

    Assistant Director, Division of Infection Control and Plastic and Reconstructive Surgery at FDA’s Center for Devices and Radiological Health (CDRH). (Plastic Surgery Skin and Wound Devices Team).

    ... read more

    Julie Morabito

    Assistant Director
    FDA

    Assistant Director, Division of Infection Control and Plastic and Reconstructive Surgery at FDA’s Center for Devices and Radiological Health (CDRH). (Plastic Surgery Skin and Wound Devices Team).

    20:50am

    R&D TRACK: Current Perspectives on Biologics in Wound Care

    • Examine biologics' effectiveness in wound care through current research, emphasizing improved patient outcomes and accelerated healing.
    • Discuss personalized medicine integration in wound care
    • Address current landscape challenges, including protocol standardization, regulatory considerations and economic implications

    Author:

    Jaideep Banerjee

    Lead Medical Science Liaisons and Clinical Strategy
    Smith & Nephew
    ... read more

    Jaideep Banerjee

    Lead Medical Science Liaisons and Clinical Strategy
    Smith & Nephew

    COMMERCIALIZATION TRACK: Exploring Investment in the Advanced Wound Care Space

    • Investigate current trends and opportunities, spotlighting investor interests and factors influencing investment decisions.
    • Discuss risk mitigation strategies in the sector, emphasizing thorough due diligence, market analysis, and regulatory understanding
    • Highlight collaboration potential between investors and industry stakeholders

    Author:

    Artem Trotsyuk

    Venture Partner
    LongeVC
    ... read more

    Artem Trotsyuk

    Venture Partner
    LongeVC

    Author:

    Ibraheem Badejo

    Senior R&D Director, External Front End Innovation
    Johnson & Johnson

    Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

    From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

    During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

    Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending

    ... read more

    Ibraheem Badejo

    Senior R&D Director, External Front End Innovation
    Johnson & Johnson

    Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

    From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

    During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

    Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending